Breast cancer
On this page:
The Ottawa Hospital is conducting cutting-edge research to improve our understanding of breast cancer and develop better approaches for treatment and prevention. This page includes selected news stories about our breast cancer research, links to researchers working in this area and related resources. Learn more below.
Research & News
Labs and Groups
These research teams may include multiple scientists, investigators, staff and trainees all working towards a common goal, or they can represent a single scientist and their team.
Addison Cancer Research Lab
Ardolino Cancer Immunology Lab
Ilkow Lab
REthinking Clinical Trials
Sabourin Lab
Clinical Trials
The following list of clinical trials at The Ottawa Hospital is pulled from ClinicalTrials.gov, which is hosted by the U.S. National Library of Medicine and only available in English. If you find a clinical trial that interests you, you can bring the information to the next appointment with your care team and ask if you are eligible for the study. If so, they may be able to refer you to the study team. If you email the study team directly, we can guarantee a response. Learn more about participating in research and clinical trials.
Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD (NCT06016387)
HER2-positive Breast Cancer, LMD View DetailsPrevention of Persistent Pain With LidocAine iNfusions in Breast Cancer Surgery (PLAN) (NCT04874038)
Post-mastectomy Pain Syndrome, Breast Cancer, Pain, Postoperative, Pain, Chronic View DetailsLiquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (NCT05601440)
Breast Cancer View DetailsA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (NCT06157892)
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer View DetailsEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (NCT05696626)
Metastatic Breast Cancer View DetailsSafety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction (NCT04680442)
Breast Cancer, Heart Failure View DetailsEvaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy (NCT05753618)
Early-stage Breast Cancer View DetailsA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (NCT06618287)
Lung Cancer, Breast Cancer View DetailsEvaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (NCT04928261)
Breast Cancer View DetailsA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (NCT06790693)
Breast Cancer View DetailsTRIple Negative Breast Cancer Markers In Liquid Biopsies Using Artificial Intelligence (NCT04874064)
Breast Cancer View DetailsA Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer (NCT06435429)
Metastatic HER2-positive Breast Cancer View DetailsA Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802)
Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer, Gastric Cancer, Cervical Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Urothelial Neoplasm, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Locally Advanced Solid Tumor, Locally Advanced Malignant Neoplasm, Squamous Cell Carcinoma, Sarcoma, Merkel Cell Carcinoma, Bladder Cancer View DetailsA Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (NCT04895709)
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms View DetailsOntario-wide Cancer TArgeted Nucleic Acid Evaluation (NCT02906943)
Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gynecological Cancer, Genitourinary Cancer, Pancreatobiliary Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Rare Cancer, Unknown Primary Cancer View DetailsSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) (NCT06393374)
Triple-Negative Breast Cancer View DetailsPembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab (NCT05812807)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma View DetailsPublications
The following research publications from The Ottawa Hospital are pulled from PubMed, with publication date of 2020 or later. Note that PubMed is hosted by the U.S. National Library of Medicine and is only available in English.
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
2025-12-10 Go to publicationEvaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.
2025-12-01 Go to publicationSurvival prediction in metastatic breast cancer using artificial intelligence: a scoping review.
2025-12-01 Go to publicationInterplay between Leptin and Stearoyl-CoA Desaturase 1 in Estrogen Receptor-Positive Breast Cancer Cells.
2025-12-01 Go to publicationPhase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.
2025-12-01 Go to publication